# Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Craig L. Leonardi,Alexa B. Kimball,Kim Papp,Newman Yeilding,Cynthia Guzzo,Yuhua Wang,Shu Li,Lisa T. Dooley,Kenneth B. Gordon |
| Citations | 1,873 |
| DOI | 10.1016/s0140-6736(08)60725-4 |
| Fields | Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2116956799 |
| PMID | 18486739 |
| Type | article |
| Year | 2008 |

## Paper authors

- [Alexa B. Kimball](https://scholariq.org/researchers/alexa-b-kimball/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Paper topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.